Silvère Baron

Dr. Silvère Baron

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
JBJulio Bunay
Julio Bunay
AFAllan Fouache
Allan Fouache
ATAmalia Trousson
Amalia Trousson
CJCyrille de Joussineau
Cyrille de Joussineau
EBErwan Bouchareb
Erwan Bouchareb
Jean-Marc LOBACCAROJean-Marc LOBACCARO
Jean-Marc LOBACCARO

1 June 2019 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
AFAllan Fouache
Allan Fouache
NZNada Zabaiou
Nada Zabaiou
CJCyrille de Joussineau
Cyrille de Joussineau
LMLaurent Morel
Laurent Morel
SSSandrine Silvente-Poirot
Sandrine Silvente-Poirot
ATAmalia Trousson
Amalia Trousson

Verified
Journal Article
Open access
PDF file
SDSarah Dallel
Sarah Dallel
ITigor tauveron
igor tauveron
FBFlorence Brugnon
Florence Brugnon
SBSilvère Baron
Silvère Baron
Jean-Marc LOBACCAROJean-Marc LOBACCARO
Jean-Marc LOBACCARO
SMSalwan Maqdasy
Salwan Maqdasy
A close relationship exists between cholesterol and female reproductive physiology. Indeed, cholesterol is crucial for steroid synthesis by ovary and placenta, and primordial for cell structure during folliculogenesis. Furthermore, oxysterols, cholesterol-derived ligands, play a potential role in oocyte maturation. Anomalies of cholesterol metabolism are frequently linked to infertility. However, little is known about the molecular mechanisms. In parallel, increasing evidence describing the biological roles of liver X receptors (LXRs) in the regulation of steroid synthesis and inflammation, two processes necessary for follicle maturation and ovulation. Both of the isoforms of LXRs and their bona fide ligands are present in the ovary. LXR-deficient mice develop late sterility due to abnormal oocyte maturation and increased oocyte atresia. These mice also have an ovarian hyper stimulation syndrome in response to gonadotropin stimulation. Hence, further studies are necessary to explore their specific roles in oocyte, granulosa, and theca cells. LXRs also modulate estrogen signaling and this could explain the putative protective role of the LXRs in breast cancer growth. Altogether, clinical studies would be important for determining the physiological relevance of LXRs in reproductive disorders in women.

17 August 2023 in Oncogene
Verified
Journal Article
Closed access
PDF file
JBJulio Buñay
Julio Buñay
MKMyriam Kossaï
Myriam Kossaï
CDChristelle Damon-Soubeyrant
Christelle Damon-Soubeyrant
AHAngélique De Haze
Angélique De Haze
JSJean-Paul Saru
Jean-Paul Saru
SBSilvère Baron
Silvère Baron

1 May 2019 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
NZNada Zabaiou
Nada Zabaiou
AFAllan Fouache
Allan Fouache
ATAmalia Trousson
Amalia Trousson
JBJulio Bunay
Julio Bunay
GMGeoffroy Marceau
Geoffroy Marceau
Jean-Marc LOBACCAROJean-Marc LOBACCARO
Jean-Marc LOBACCARO

Verified
Journal Article
Open access
PDF file
BBBagora Bayala
Bagora Bayala
AZAbdou Azaque ZOURE
Abdou Azaque ZOURE
SBSilvère Baron
Silvère Baron
CJCyrille de Joussineau
Cyrille de Joussineau
JSJacques SIMPORE
Jacques SIMPORE
Jean-Marc LOBACCAROJean-Marc LOBACCARO
Jean-Marc LOBACCARO
The great majority of breast and prostate tumors are hormone-dependent cancers; hence, estrogens and androgens can, respectively, drive their developments, making it possible to use pharmacological therapies in their hormone-dependent phases by targeting the levels of steroid or modulating their physiological activity through their respective nuclear receptors when the tumors relapse. Unfortunately, at some stage, both breast and prostate cancers become resistant to pharmacological treatments that aim to block their receptors, estrogen (ER) or androgen (AR) receptors, respectively. So far, antiestrogens and antiandrogens used in clinics have been designed based on their structural analogies with natural hormones, 17-β estradiol and dihydrotestosterone. Plants are a potential source of drug discovery and the development of new pharmacological compounds. The aim of this review article is to highlight the recent advances in the pharmacological modulation of androgen or estrogen levels, and their activity through their cognate nuclear receptors in prostate or breast cancer and the effects of some plants extracts.